Commercial insurance delays direct-acting antiviral treatment for hepatitis C kidney transplantation into uninfected recipients.

Julia TorabiJuan P RoccaMaria AjaimyJeffrey MelvinAlesa CampbellEnver AkalinLuz E LirianoYorg AzziCindy PynadathStuart M GreensteinMarie LeDoctor Y GoldsteinAmy S FoxJin CarreroJeffrey M WeissTia PowellAndrew D RacineJohn F ReinusMilan M KinkhabwalaJay A Graham

Published in: Transplant infectious disease : an official journal of the Transplantation Society (2020)

D+/R- transplantation offers patients an alternative strategy to increase access. However, treatment can be profoundly delayed by a third-party payer authorization process that may be subjecting patients to unnecessary risks and worsened outcomes.

Keyphrases

end stage renal disease
kidney transplantation
newly diagnosed
chronic kidney disease
ejection fraction
prognostic factors
peritoneal dialysis
stem cells
hiv infected
type diabetes
mesenchymal stem cells
health insurance
skeletal muscle
risk assessment
combination therapy